Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Cerilliant
McKinsey
Mallinckrodt
Julphar
Johnson and Johnson
Novartis
Colorcon
Fuji
AstraZeneca

Generated: February 22, 2018

DrugPatentWatch Database Preview

Eli Lilly Co Company Profile

« Back to Dashboard

Summary for Eli Lilly Co
International Patents:279
US Patents:4
Tradenames:2
Ingredients:2
NDAs:2
Drug Master File Entries: 1

Drugs and US Patents for Eli Lilly Co

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly Co ADCIRCA tadalafil TABLET;ORAL 022332-001 May 22, 2009 RX Yes Yes 5,859,006*PED ➤ Try a Free Trial ➤ Try a Free Trial
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-001 Dec 11, 2009 RX Yes No 6,169,084 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Eli Lilly Co ADCIRCA tadalafil TABLET;ORAL 022332-001 May 22, 2009 RX Yes Yes 7,182,958*PED ➤ Try a Free Trial Y ➤ Try a Free Trial
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-002 Dec 11, 2009 RX Yes No 6,169,084 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Eli Lilly Co ADCIRCA tadalafil TABLET;ORAL 022332-001 May 22, 2009 RX Yes Yes 6,821,975*PED ➤ Try a Free Trial Y ➤ Try a Free Trial
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-003 Dec 11, 2009 RX Yes Yes 6,169,084 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Eli Lilly Co

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-001 Dec 11, 2009 5,229,382*PED ➤ Try a Free Trial
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-002 Dec 11, 2009 5,229,382*PED ➤ Try a Free Trial
Eli Lilly Co ZYPREXA RELPREVV olanzapine pamoate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173-003 Dec 11, 2009 5,229,382*PED ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ELI LILLY CO drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 20 mg ➤ Subscribe 10/15/2009

Non-Orange Book US Patents for Eli Lilly Co

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,981,527 Cyclic GMP-specific phosphodiesterase inhibitors ➤ Try a Free Trial
6,140,329 Use of cGMP-phosphodiesterase inhibitors in methods and compositions to treat impotence ➤ Try a Free Trial
6,617,321 2-methyl-thieno-benzodiazepine formulation ➤ Try a Free Trial
6,143,746 Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use ➤ Try a Free Trial
6,608,065 Use of cGMP phosphodiesterase inhibitors in methods to treat female sexual dysfunction ➤ Try a Free Trial
7,303,764 2-methyl-thieno-benzodiazepine formulation ➤ Try a Free Trial
6,784,179 Tetracyclic derivatives, process of preparation and use ➤ Try a Free Trial
6,369,059 Tetracyclic derivatives, process of preparation and use ➤ Try a Free Trial
6,025,494 Tetracyclic derivatives, process of preparation and use ➤ Try a Free Trial
6,127,542 Tetracyclic derivatives, process of preparation and use ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Eli Lilly Co Drugs

Supplementary Protection Certificates for Eli Lilly Co Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C004/2003 Ireland ➤ Try a Free Trial SPC004/2003, 20040610, EXPIRES: 20171111
70015 Netherlands ➤ Try a Free Trial PRODUCT NAME: OLANZAPINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT; REGISTRATION NO/DATE: EU/1/96/022/001 - EU/1/96/022/010 19960927
2016 00024 Denmark ➤ Try a Free Trial PRODUCT NAME: AMBRISENTAN USED IN COMBINATION TREATMENT WITH TADALAFIL; REG. NO/DATE: EU/1/08/451 (001-004) 20151125
2016000039 Germany ➤ Try a Free Trial PRODUCT NAME: AMBRISENTAN IN VERWENDUNG IN DER KOMBINATIONSTHERAPIE MIT TADALAFIL; REGISTRATION NO/DATE: EU/1/08/451 20151120
C/GB03/007 United Kingdom ➤ Try a Free Trial PRODUCT NAME: TADALAFIL AND PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS AND SOLVATES THEREOF.; REGISTERED: UK EU/1/02/237/001-004 20021114
2003001 Lithuania ➤ Try a Free Trial PRODUCT NAME: TADALAFILUM ((6R,12AR)-2,3,6,7,12,12A-HEKSAHIDRO-2-METIL-6-(3,4-METILENDIOKSIFENIL)-PIRAZINO(2',1':6,1)PIRIDO(3,4-B)INDOL-1,4-DIONAS); REGISTRATION NO/DATE: 03/8034/3, 03/8035/3 20030328
0813 Netherlands ➤ Try a Free Trial PRODUCT NAME: AMBRISENTAN TOEGEPAST IN COMBINATIEBEHANDELING MET TADALAFIL; REGISTRATION NO/DATE: EU/1/08/451 (C(2008) 1637) 20151125
081 Luxembourg ➤ Try a Free Trial PRODUCT NAME: AMBRISENTAN UTILISE EN TRAITEMENT COMBINE AVEC TADALAFIL; FRIST REGISTRATION: 20151125
0124 Netherlands ➤ Try a Free Trial 300124, 20150119, EXPIRES: 20171111
C/GB96/058 United Kingdom ➤ Try a Free Trial PRODUCT NAME: OLANZAPINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/96/022/001 19960927; UK EU/1/96/022/002 19960927; UK EU/1/96/022/003 19960927; UK EU/1/96/022/004 19960927; UK EU/1/96/022/005 19960927; UK EU/1/96/022/006 19960927; UK EU/1/96/022/007 19960927; UK EU/1/96/022/008 19960927; UK EU/1/96/022/009 19960927; UK EU/1/96/022/010 19960927
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
US Army
Chinese Patent Office
Cipla
Citi
QuintilesIMS
Johnson and Johnson
Covington
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot